Royal Bank of Canada’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-605
| Closed | -$11K | – | 7936 |
|
|
2020
Q4 | $11K | Buy |
605
+500
| +476% | +$9.11K | ﹤0.01% | 6358 |
|
|
2020
Q3 | $2K | Buy |
105
+85
| +425% | +$1.43K | ﹤0.01% | 6370 |
|
|
2020
Q2 | $0 | Sell |
20
-48
| -71% | -$686 | ﹤0.01% | 7106 |
|
|
2020
Q1 | $1K | Sell |
68
-809
| -92% | -$13.1K | ﹤0.01% | 6576 |
|
|
2019
Q4 | $14K | Buy |
+877
| New | +$14.6K | ﹤0.01% | 6037 |
|
|
2018
Q4 | – | Sell |
-249
| Closed | -$5K | – | 7358 |
|
|
2018
Q3 | $5K | Buy |
+249
| New | +$5.11K | ﹤0.01% | 6306 |
|
|
2017
Q4 | – | Sell |
-3
| Closed | – | – | 7086 |
|
|
2017
Q3 | $0 | Buy |
+3
| New | +$28 | ﹤0.01% | 7125 |
|
|
2017
Q2 | – | Sell |
-550
| Closed | -$6K | – | 6911 |
|
|
2017
Q1 | $6K | Sell |
550
-195
| -26% | -$2.37K | ﹤0.01% | 6168 |
|
|
2016
Q4 | $10K | Buy |
+745
| New | +$9.97K | ﹤0.01% | 6102 |
|
|
2016
Q1 | – | Sell |
-8
| Closed | – | – | 6793 |
|
|
2015
Q4 | $0 | Sell |
8
-488
| -98% | -$10.3K | ﹤0.01% | 6934 |
|
|
2015
Q3 | $8K | Sell |
496
-61
| -11% | -$1.52K | ﹤0.01% | 6005 |
|
|
2015
Q2 | $21K | Buy |
+557
| New | +$18K | ﹤0.01% | 5684 |
|
Royal Bank of Canada's CBMG Position: Q1 2021 in Review
Royal Bank of Canada sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 605 shares — an estimated $11K sold.
Royal Bank of Canada first reported a position in CBMG in Q2 2015 and held it in 12 quarters. The position peaked at $21K in Q2 2015. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Royal Bank of Canada reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Royal Bank of Canada sold 605 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $11K.
- Royal Bank of Canada first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 12 quarters.
- Royal Bank of Canada's Cellular Biomedicine Group, Inc. position peaked at $21K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Royal Bank of Canada's 13F filing for Q1 2021, filed 17 May 2021.